Actinium to present Phase 1 data on ATNM-400 at EANM 2026
Tweet Send to a Friend
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced that early results from a first-in-human Phase 1 study of its experimental cancer ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




